Bioxcel therapeutics initiates pivotal phase 3 program of bxcl501 for acute treatment of agitation in patients with alzheimer's disease

Two phase 3 studies to enroll a total of 300 patients in assisted living or residential facilities and nursing homes to evaluate the safety and efficacy of bxcl501

BTAI Ratings Summary

BTAI Quant Ranking